Diabetes and hypertension are leading causes of chronic kidney disease (CKD) and end-stage renal disease (ESRD). As the prevalence of diabetes and hypertension increases globally, so does the number of individuals at risk of developing kidney disease and requiring dialysis treatment.
For instance, according to World Diabetes Day, 537 million adults around the world were living with diabetes in 2021. This number is expected to rise to 643 million by 2030 and 783 million by 2045. Similarly, according to the World Heart Federation, 1.3 billion people around the world are affected with hypertension.
Diabetes and hypertension can damage the small blood vessels in the kidneys over time, leading to reduced kidney function and eventual kidney failure. Individuals with uncontrolled diabetes or hypertension are at a higher risk of developing complications such as diabetic nephropathy or hypertensive nephropathy, necessitating dialysis or kidney transplantation for survival.
Moreover, diabetes and hypertension often coexist with other chronic conditions such as cardiovascular disease, obesity, and dyslipidemia, further increasing the risk of kidney damage and progressive kidney dysfunction.
The presence of multiple comorbidities complicates disease management and may necessitate multidisciplinary care, including dialysis treatment, to address the complex health needs of affected individuals.
Thus, with the increasing prevalence of chronic diseases such as diabetes and hypertension, the market is expected to experience robust growth in the coming years.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
The global dialysis services market was valued at USD 77.1 billion in 2023 and will grow at 5.1% CAGR during 2024-2032, driven by rising number of end stage renal diseases (ESRD) patients.
Hemodialysis from type segment held a significant market share of 88.2% in 2023 and will grow rapidly till 2032, owing to its safety, efficacy, and convenience.
North America dialysis services market was valued at USD 36.1 billion in 2023 and will grow at 4% CAGR over the analysis timeframe, due to its strong healthcare services industry.
Atlantic Dialysis Management Services, LLC, Baxter International Inc., Centers for Dialysis Care, DaVita Inc., Dialysis Clinic, Inc., Diaverum AB, Fresenius Medical Care, HATTIESBURG CLINIC among others.